152 related articles for article (PubMed ID: 33228460)
21. Identification of molecular descriptors for design of novel Isoalloxazine derivatives as potential Acetylcholinesterase inhibitors against Alzheimer's disease.
Gurung AB; Aguan K; Mitra S; Bhattacharjee A
J Biomol Struct Dyn; 2017 Jun; 35(8):1729-1742. PubMed ID: 27410776
[TBL] [Abstract][Full Text] [Related]
22. A new role for the nonpathogenic nonsynonymous single-nucleotide polymorphisms of acetylcholinesterase in the treatment of Alzheimer's disease: a computational study.
Saravanaraman P; Chinnadurai RK; Boopathy R
J Comput Biol; 2014 Aug; 21(8):632-47. PubMed ID: 24611490
[TBL] [Abstract][Full Text] [Related]
23. Potential alternatives to current cholinesterase inhibitors: an
Kundu D; Dubey VK
Drug Dev Ind Pharm; 2021 Jun; 47(6):919-930. PubMed ID: 34219594
[TBL] [Abstract][Full Text] [Related]
24. Donepezil Inhibits Acetylcholinesterase via Multiple Binding Modes at Room Temperature.
Silva MA; Kiametis AS; Treptow W
J Chem Inf Model; 2020 Jul; 60(7):3463-3471. PubMed ID: 32096991
[TBL] [Abstract][Full Text] [Related]
25. Deciphering the Interactions of Bioactive Compounds in Selected Traditional Medicinal Plants against Alzheimer's Diseases via Pharmacophore Modeling, Auto-QSAR, and Molecular Docking Approaches.
Ojo OA; Ojo AB; Okolie C; Nwakama MC; Iyobhebhe M; Evbuomwan IO; Nwonuma CO; Maimako RF; Adegboyega AE; Taiwo OA; Alsharif KF; Batiha GE
Molecules; 2021 Apr; 26(7):. PubMed ID: 33915968
[TBL] [Abstract][Full Text] [Related]
26. Classics in Chemical Neuroscience: Donepezil.
Brewster JT; Dell'Acqua S; Thach DQ; Sessler JL
ACS Chem Neurosci; 2019 Jan; 10(1):155-167. PubMed ID: 30372021
[TBL] [Abstract][Full Text] [Related]
27. Design and synthesis of donepezil analogues as dual AChE and BACE-1 inhibitors.
Gabr MT; Abdel-Raziq MS
Bioorg Chem; 2018 Oct; 80():245-252. PubMed ID: 29966870
[TBL] [Abstract][Full Text] [Related]
28. Modulatory effect of caffeic acid on cholinesterases inhibitory properties of donepezil.
Agunloye OM; Oboh G
J Complement Integr Med; 2017 Sep; 15(1):. PubMed ID: 28941354
[TBL] [Abstract][Full Text] [Related]
29. A Systematic Review on Donepezil-based Derivatives as Potential Cholinesterase Inhibitors for Alzheimer's Disease.
Korabecny J; Spilovska K; Mezeiova E; Benek O; Juza R; Kaping D; Soukup O
Curr Med Chem; 2019; 26(30):5625-5648. PubMed ID: 29768996
[TBL] [Abstract][Full Text] [Related]
30. Potential acetylcholinesterase inhibitors: molecular docking, molecular dynamics, and in silico prediction.
Kiametis AS; Silva MA; Romeiro LA; Martins JB; Gargano R
J Mol Model; 2017 Feb; 23(2):67. PubMed ID: 28185116
[TBL] [Abstract][Full Text] [Related]
31. Potential Therapeutic Agents on Alzheimer's Disease through Molecular Docking and Molecular Dynamics Simulation Study of Plant-Based Compounds.
Borah K; Bora K; Mallik S; Zhao Z
Chem Biodivers; 2023 Jan; 20(1):e202200684. PubMed ID: 36480442
[TBL] [Abstract][Full Text] [Related]
32. Discovery of drug-like acetylcholinesterase inhibitors by rapid virtual screening of a 6.9 million compound database.
Miles JA; Ng JH; Sreenivas BY; Courageux C; Igert A; Dias J; McGeary RP; Brazzolotto X; Ross BP
Chem Biol Drug Des; 2021 May; 97(5):1048-1058. PubMed ID: 33455074
[TBL] [Abstract][Full Text] [Related]
33. Investigating molecular interactions between human transferrin and resveratrol through a unified experimental and computational approach: Role of natural compounds in Alzheimer's disease therapeutics.
Khan MS; Furkan M; Shahwan M; Yadav DK; Anwar S; Khan RH; Shamsi A
Amino Acids; 2023 Dec; 55(12):1923-1935. PubMed ID: 37926707
[TBL] [Abstract][Full Text] [Related]
34. Discovery of potential inhibitor against human acetylcholinesterase: a molecular docking and molecular dynamics investigation.
Singh SP; Gupta D
Comput Biol Chem; 2017 Jun; 68():224-230. PubMed ID: 28432980
[TBL] [Abstract][Full Text] [Related]
35. Thiazole-substituted benzoylpiperazine derivatives as acetylcholinesterase inhibitors.
Sahin Z; Ertas M; Bender C; Bülbül EF; Berk B; Biltekin SN; Yurttaş L; Demirayak Ş
Drug Dev Res; 2018 Dec; 79(8):406-425. PubMed ID: 30343499
[TBL] [Abstract][Full Text] [Related]
36. In silico identification of AChE and PARP-1 dual-targeted inhibitors of Alzheimer's disease.
Hu XM; Dong W; Cui ZW; Gao CZ; Yu ZJ; Yuan Q; Min ZL
J Mol Model; 2018 Jun; 24(7):151. PubMed ID: 29869722
[TBL] [Abstract][Full Text] [Related]
37. Donepezil-Based Central Acetylcholinesterase Inhibitors by Means of a "Bio-Oxidizable" Prodrug Strategy: Design, Synthesis, and in Vitro Biological Evaluation.
Peauger L; Azzouz R; Gembus V; Ţînţaş ML; Sopková-de Oliveira Santos J; Bohn P; Papamicaël C; Levacher V
J Med Chem; 2017 Jul; 60(13):5909-5926. PubMed ID: 28613859
[TBL] [Abstract][Full Text] [Related]
38. Binding interaction of protoberberine alkaloids against acetylcholinesterase (AChE) using molecular dynamics simulations and QM/MM calculations.
Honorio P; Sainimnuan S; Hannongbua S; Saparpakorn P
Chem Biol Interact; 2021 Aug; 344():109523. PubMed ID: 34033838
[TBL] [Abstract][Full Text] [Related]
39. In silico analyses of acetylcholinesterase (AChE) and its genetic variants in interaction with the anti-Alzheimer drug Rivastigmine.
Pereira GRC; Gonçalves LM; Abrahim-Vieira BA; De Mesquita JF
J Cell Biochem; 2022 Jul; 123(7):1259-1277. PubMed ID: 35644025
[TBL] [Abstract][Full Text] [Related]
40. Discovery of dual cation-π inhibitors of acetylcholinesterase: design, synthesis and biological evaluation.
Damuka N; Kammari K; Potshangbam AM; Rathore RS; Kondapi AK; Vindal V
Pharmacol Rep; 2020 Jun; 72(3):705-718. PubMed ID: 32200493
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
